Drug Discovery from Marine Microbes

Microbial Ecology

Volumn 65, Issue 4, 2013, Pages 800-806

  Gerwick, William H ^a,b   Fenner, Amanda M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; SEA WATER;

ANIMAL; AQUATIC SPECIES; BACTERIUM; CHEMISTRY; DRUG DEVELOPMENT; INVERTEBRATE; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; REVIEW; SYMBIOSIS;

ANIMALS; AQUATIC ORGANISMS; BACTERIA; BIOLOGICAL AGENTS; DRUG DISCOVERY; INVERTEBRATES; SEAWATER; SYMBIOSIS;

INVERTEBRATA;

EID: 84876928207     PISSN: 00953628     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00248-012-0169-9     Document Type: Review

References (31)

1. Blunt J, Munro M, Upjohn M (2012) The role of databases in marine natural products research. In: Fattorusso E, Gerwick WH, Taglialatela-Scafati O (eds) Handbook of marine natural products, 1st edn. Springer, Dordrecht, pp 389-421.
2. Gerwick WH, Moore BS (2012) Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chem Biol 19: 85-98.
3. Mayer AMS, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE (2010) The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 31: 255-265.
4. Newman DJ, Cragg GM (2010) Natural products derivatives and mimics as antitumor agents. In: Wrigley S, Thomas R, Nicholson N, Bedford C (eds) Functional molecules from natural sources. RSC, Cambridge, pp 3-36.
5. Lichter W, Lopez DM, Wellham LL, Sigel MM (1975) Ecteinascidia turbinata extracts inhibit DNA synthesis in lymphocytes after mitogenic stimulation by lectins. Proc Soc Exp Biol Med 150: 475-478.
6. Rinehart KL, Holt TG, Fregeau NL, Stroh JG, Keifer PA, Sun F, Li LH, Martin DG (1990) Ecteinascidins 729 743 745 759A 759B and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinate. J Org Chem 55: 4512-4215.
7. Wright AE, Forleo DA, Gunawardana GP, Gunasekera SP, Koehn FE, McConnell OJ (1990) Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinate. J Org Chem 55: 4508-4512.
8. Mendola D, Naranjo L, Santiago A, Duckworth AR, Osinga R (2006) The promise of aquaculture for delivering sustainable supplies of new drugs from the sea: examples from in-sea and tank-based invertebrate culture projects from around the world. In: Proksch P, Müller WEG (eds) Frontiers in marine biotechnology. Horizon Bioscience, Norwich, pp 21-72.
9. Corey EJ, Gin DY, Kania RS (1996) Enantioselective total synthesis of ecteinascidin 743. J Am Chem Soc 118: 9202-9203.
10. Cuevas C, Pérez M, Martín MJ, Chicharro JL, Fernández-Rivas C, Flores M, Francesch A, Gallego P, Zarzuelo M, de la Calle F, García J et al (2000) Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org Lett 2: 2545-2548.
11. Rath CM, Janto B, Earl J, Ahmed A, Hu FZ, Hiller L, Dahlgren M, Kreft R, Yu F, Wolff JJ et al (2011) Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743. ACS Chem Biol 6: 1244-1256.
12. Scotto KW (2002) ET-743: more than an innovative mechanism of action. Anti-Cancer Drugs 13: S3-S6.
13. Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 109: 6883-6885.
14. Hamel E (1993) Potent new antimitotic natural products from marine animals which act in the vinca domain of tubulin. Cell Pharm 1: S47-S52.
15. Luesch H, Moore RE, Paul VJ, Mooberry SL, Corbett TH (2001) Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod 64: 907-910.
16. Pitot HC, McElroy EA Jr, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM et al (1999) Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5: 525-531.
17. Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotech 30: 631-637.
18. Hirata Y, Uemura D (1986) Halichondrins-antitumor polyether macrolides from a marine sponge. Pure Appl Chem 58: 701-710.
19. Munro MHG, Blunt JW, Dumdei EJ, Hickford SJH, Lill RE, Li S, Battershill CN, Duckworth AR (1999) The discovery and development of marine compounds with pharmaceutical potential. Prog Indus Micro 35: 15-25.
20. Yu MJ, Zheng W, Seletsky BM, Littlefield BA, Kishi Y (2011) Case history: discovery of eribulin (HALAVEN), a halichondrin B analogue that prolongs overall survival in patients with metastatic breast cancer. Ann Rep Med Chem 46: 227-241.
21. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE et al (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15: 4207-4212.
22. Towle MJ, Nomoto K, Asano M, Kishi Y, Yu MJ, Littlefield BA (2012) Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. Anticancer Res 32: 1611-1619.
23. Jones AC, Monroe EA, Eisman E, Gerwick L, Sherman DH, Gerwick WH (2010) The unique mechanistic transformations involved in the biosynthesis of modular natural products from marine cyanobacteria. Nat Prod Rep 27: 1048-1065.
24. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W et al (2011) Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 11: 254-284.
25. Groll M, Huber R, Potts BC (2006) Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128: 5136-5141.
26. Fenical W, Jensen PR (2006) Developing a new resource for drug discovery: marine actinomycete bacteria. Nat Chem Biol 2: 666-673.
27. Chang F-Y, Brady SF (2011) Cloning and characterization of an environmental DNA-derived gene cluster that encodes the biosynthesis of the antitumor substance BE-54017. J Am Chem Soc 133: 9996-9999.
28. Guthals A, Watrous JD, Dorrestein PC, Bandeira N (2012) The spectral networks paradigm in high throughput mass spectrometry. Mol BioSys 8: 2535-2544.
29. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10: 507-519.
30. Penrod NM, Cowper-Sal-lari R, Moore JH (2011) Systems genetics for drug target discovery. Trends Pharm Sci 32: 623-630.
31. Pawlik JR (2011) The chemical ecology of sponges on Caribbean reefs: natural products shape natural systems. BioScience 61: 888-898.